Vaccine Adjuvants Market Forecasts to 2028 – Global Analysis By Type (Virus-like Particles, Tensoactive Adjuvants, Organic Adjuvants), Product (Adjuvant Emulsions, Combination Adjuvants), Disease Type (Cancer, Infectious Diseases) and By Geography

Vaccine Adjuvants Market Forecasts to 2028 – Global Analysis By Type (Virus-like Particles, Tensoactive Adjuvants, Organic Adjuvants), Product (Adjuvant Emulsions, Combination Adjuvants), Disease Type (Cancer, Infectious Diseases) and By Geography

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $791.00 million in 2021 and is expected to reach $2,040.87 million by 2028 growing at a CAGR of 14.5% during the forecast period. Adjuvants are fundamentally compounds that improve the body’s immunogenic reaction against antigens. As a result, these are majorly added to vaccines to increase their capability to influence long-term protection and safety against any kind of viruses. Currently, MF59 and aluminum salts are the only adjuvants which are viable for human usage. There have been a lot of developments done on the antigen discovery over the past decade which has enhanced the vaccine development process.

Market Dynamics:

Driver:

Rising Incidence of Naïve Infectious Chronic Diseases

The upsurge in the prevalence of cervical cancer, infectious diseases like Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are predicted to drive the market. Moreover, in recent years there has been an increasing focus on developing more efficient and longer-lasting vaccination against current and new diseases. The current onset of the Covid-19 pandemic is expected to create massive growth opportunities for the development of the global market. The research and development activities for creating a vaccine for Covid-19 have been underway at full force. With over a million cases across the globe and more than 160 countries affected, it has become imperative to find a vaccine for the infection. This will present a promising demand for the overall development of the market.

Restraint:

High Cost of Raw material

The increasing costs of the raw materials which in turn have lifted the cost of manufacturing are a few of the factors hindering the growth of the market. The cost of developing new vaccine adjuvants, the high toxicity of adjuvants on application, huge investment required for developing a new adjuvant, and strict regulatory requirements are some restraining factors that are expected to hamper the global vaccine adjuvants market growth.

Opportunity:

Increasing Research & Development

Increased levels of spending and funding allocated for the development of more efficient vaccine adjuvants. The regional segment of Western Europe and the APEJ segment is next in line after North America in terms of revenue generation. Increasing government initiatives for vaccinations and the high prevalence of infectious & zoonotic diseases are accelerating the growth of the market. An increasing technological advancement focusing on improved & long-lasting vaccines for existing and emerging chronic diseases is creating ample opportunity for the market.

Threat:

Side Effects

Adjuvanted vaccines can cause more local reactions (such as redness, swelling, and pain at the injection site) and more systemic reactions (such as fever, chills, and body aches) than non-adjuvanted vaccines. Side effects of adjuvants will further derail the market growth rate. The high manufacturing cost of these drugs will also create hindrances to the growth of this market.

Particulate Adjuvants segment is expected to be the largest during the forecast period

The Particulate segment is expected to hold the largest market share while adjuvant emulsion segment is predicted to grow with the highest CAGR. The factors can be attributed to the growing prevalence of diseases such as allergy, cancer, & HIV/AIDS, development of improved vaccine immunization, and rising demand for advanced treatment options.

The Intramuscular Route segment is expected to have the highest CAGR during the forecast period

The intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.

Region with highest share:

The Asia Pacific is projected to hold the highest market share. The growth in this market cantered at China and India. Increasing incidence of infectious diseases, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian province. Moreover, the continuously improving healthcare facilities such as the availability of medicines, coupled with the increase in research & development funding to meet the huge unmet demands. This is expected to increase the market share over the forecast period.

Region with highest CAGR:

North America is projected to have the highest CAGR, owing to high adoption of the innovative products and incidence of major market players in this province especially in the United States. Further, favourable government support towards the growth of healthcare infrastructure is also contributing the growth of the vaccine adjuvants market in this region.

Key players in the market:

Some of the key players profiled in the Vaccine Adjuvants Market include Adjuvance Technologies, Inc, Adjuvatis, Agenus, Inc, Aphios Corp, Avanti Polar Lipids, CSL Limited, CureVac AG, GSK, Invivogen, Kineta, Inc, MVP Laboratories, Inc, Novartis/CSL, Novavax, Inc, OZ Biosciences, Sergeant Adjuvants, Sigma Aldrich (Merck KGaA), Vaxine Pty Ltd, Vaxliant, Viscogel AB, Sanofi, SK bioscience.

Key developments:

In February 2022: Sanofi and GSK intends to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

In August 2021: SK bioscience and GlaxoSmithKline plc (GSK) initiated a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results..

Types Covered:
• Virus-like Particles
• Tensoactive Adjuvants
• Organic Adjuvants
• Mineral Salt based Adjuvants
• Liposomes
• Emulsions
• Carbohydrates Adjuvants
• Bacteria-derived Adjuvants

Products Covered:
• Adjuvant Emulsions
• Combination Adjuvants
• Particulate Adjuvants
• Pathogen Components
• Saponin

Disease Types Covered:
• Cancer
• Infectious Diseases

Mechanism of Actions Covered:
• Vehicle Adjuvants
• Carriers
• Active Immunostimulants

Route of Administrations Covered:
• Subcutaneous Route
• Oral Route
• Intranasal Route
• Intramuscular Route
• Intradermal Route

Applications Covered:
• Veterinary Vaccine Adjuvants
• Human Vaccine Adjuvants

End Users Covered:
• Research Institutes
• Pharmaceutical Companies
• Contract Manufacturing Organization
• Commercial
• Pediatric
• Adults

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances